Trials / Terminated
TerminatedNCT04346355
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients
An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Azienda USL Reggio Emilia - IRCCS · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The clinical study aims at assessing whether early administration of Tocilizumab compared to late administration of Tocilizumab can reduce the number of patients with COVID-19 pneumonia who require mechanical ventilation. The clinical study includes patients with recent-onset COVID-19 pneumonia who require hospital care, but not invasive or semi-invasive mechanical ventilation procedures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tocilizumab | In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours |
Timeline
- Start date
- 2020-03-31
- Primary completion
- 2020-06-06
- Completion
- 2020-06-06
- First posted
- 2020-04-15
- Last updated
- 2020-06-22
Locations
25 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04346355. Inclusion in this directory is not an endorsement.